EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Rafaèle Tordjman

Valuing your startup: How does the valuation process work?

Sofinnova Partners

Ed Silverman

What's the next big thing on pharma's wish list?

STAT News

7:30am 7:30am (0 mins)

Networking

Registration, exhibition and breakfast

Level 4

8:00am 6:00pm (600 mins)

Pitch and Partner

One-to-one meetings

8:30am 10:00am (90 mins)

Pitch and Partner

Pharma and large biotech presentations

Hear the latest partnering opportunities from global pharma companies.

9:30am 12:15pm (165 mins)

Pitch and Partner

Biotech presentations

8:30am 9:00am (30 mins)

Translational Impact Forum

Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development

From Bedside to Bench and Back Again: Using Clinical Data to Develop Translatable Models for Drug Discovery

8:30 am – Welcome and live broadcast start

Speaker: James C. Foster

  • Speaker James C. Foster - Chairman, President and CEO, Charles River

9:00am 12:20pm (200 mins)

Translational Impact Forum

Keynotes

9:00 am – Application of genomic data to immuno-oncology

Speaker: Francesco Marincola, MD, FACS

10:00 am – Break

10:20 am – Translating animal studies to successful human therapies

Speaker: James M. Wilson, MD, PhD

11:20 am – TBD

Speaker: David M. Sabatini, MD, PhD


  • Speaker Francesco Marincola, MD, FACS - Distinguished Research Fellow in Immuno-Oncology, AbbVie
  • Speaker David Sabatini, MD, PhD - Member, Whitehead Institute; Professor of Biology, MIT; Investigator of the Howard Hughes Medical Institute; Senior Associate Member, Broad Institute
  • Speaker James. Wilson, MD, PhD - Professor, Internal Medicine and Pathology amd Laboratory Medicine; Director, Gene Therapy Program,, Perelman School of Medicine, University of Pennsylvania

10:00am 10:15am (15 mins)

Startup Program

Introduction

10:30am 11:15am (45 mins)

Startup Program

EBD Academy Buzz Session: Taking a look at the softer side of negotiation

A short buzz training session delivered by EBD Academy 

Overview  

This short and concise session will examine the “softer side of negotiation” providing you with deeper insights into the human mind during negotiations, better assisting you in future deals. Most professionals focus on the process, tactics and the importance of uncovering important insights into the other party's needs. This brief presentation will provide examples showing that things are not always as they appear and the human mind does not always think rationally and logically. 

Session breakdown 

The following areas will be discussed during the session  

  • Confirmation bias 
  • Overconfidence 
  • Competitor's neglect  
  • Risk and loss aversion  
  • Fairness and anchoring  
  • The importance of influence and persuasion skills   

What is a Buzz session? 

Delivered by EBD Academy and developed in partnership with EBD Group, buzz sessions will provide attendees with take-away skills and knowledge that will benefit them while at the event and in their professional careers. All buzz sessions are designed to be concise, informative and engaging which creates a learning environment that is exciting to be a part of.  

Benefits of attending a Buzz session 

  • Gain practical skills that can be implemented immediately at the EBD event  
  • High intensity sessions designed to improve your skillset  
  • Interactive 
  • Learn from the expert and others attending the session   
  • Concise and informative
  • Trainer Anjan Aralihalli - Chief Business Officer, GLyPharma Therapeutic

11:15am 11:30am (15 mins)

Startup Program

How to tell your story

  • Speaker Hal Mackins - Senior Partner, Torch Communications

11:30am 11:45am (15 mins)

Startup Program

Establishing and protecting your IP

  • Speaker Asher Rubin - Global Head, Life Sciences and Healthcare Industry Group, Hogan Lovells
  • Speaker Cullen Taylor - Partner, Hogan Lovells

11:45am 12:00pm (15 mins)

Startup Program

The partnership before the partnership: Working with a CRO to get the most out of your first trial

12:00pm 12:15pm (15 mins)

Startup Program

Valuing your startup: How does the valuation process work?

  • Speaker Rafaèle Tordjman - Special Advisor, Sofinnova Partners

12:15pm 1:15pm (60 mins)

Networking

Luncheon

1:15pm 3:30pm (135 mins)

Pitch and Partner

Biotech Presentations

1:30pm 4:50pm (200 mins)

Translational Impact Forum

TRACK ONE: Improving translatability of animal models in drug discovery

1:30 pm – DIAMOND mice for the study of NASH

Speaker: Arun Sanyal, MD

2:30 pm – Exercise capacity, ageing and longevity

Speaker: Lauren Koch, PhD

3:30 pm – Break

3:50 pm –Diet preferences in large animal models of cardiovascular disease: Does it matter?

Speaker: Anthony Comuzzie, PhD, FTOS

  • Speaker Anthony Comuzzie, PhD, FTOS - Executive Director, The Obesity Society
  • Speaker Lauren Koch, PhD - Associate Professor, University of Michigan Medical School, Ann Arbor
  • Speaker Arun Sanyal, MD - Professor, Department of Internal Medicine Division of Gastroenterology, Virginia Commonwealth University

1:30pm 4:50pm (200 mins)

Translational Impact Forum

TRACK TWO:  Non-traditional animal models for drug discovery

1:30 pm – Small molecule discovery for regenerative medicine: The essential role of non-traditional animal models

Speaker: Kevin Strange, PhD

2:30 pm – Bugs as drugs

Speaker: Paul Miller, PhD

3:30 pm – Break

3:50 pm – Rapid 3D bioprinting of blood vessel network and microphysiological systems

Speaker: Shaochen Chen, PhD

  • Speaker Shaochen Chen, PhD - Professor, University of California, San Diego
  • Speaker Paul Miller, PhD - Chief Scientific Officer, Synlogic Therapeutics
  • Speaker Kevin Strange, PhD - President and CEO, MDI Biological Laboratory; Co-Founder and CEO, Novo Biosciences, Inc.

1:30pm 4:50pm (200 mins)

Translational Impact Forum

TRACK THREE:  How reverse translation has influenced animal model creation

1:30 pm – Mouse models for atherosclerosis

Speaker: Alan Daugherty, PhD, DSc, FAHA

2:30 pm – Recapitulating human patient mutations in mouse oncology models

Speaker: Dejan Juric, MD

3:30 pm – Break 

3:50 pm – Rat models of susceptibility to complex diseases: A solution to Eroom's law

Speaker: Steven Britton, PhD

  • Speaker Steven Britton, PhD - Professor of Anesthesiology, Professor of Molecular and Integrative Physiology, University of Michigan School of Medicine
  • Speaker Alan Daugherty, PhD, DSc, FAHA - Associate VP for Research; Senior Associated Dean for Research, College of Medicine Chair, Department of Physiology; Director, Saha Cardiovascular Research Center, Gill Foundation Chair in Preventive Cardiology, Professor of Medicine and Physiology, University of Kentucky, ATVB, Editor in Chief, University of Kentucky College of Medicine
  • Speaker Dejan Juric, MD - Director of Translational Research, Termeer Center for Targeted Therapies, Massachusetts General Hospital

1:30pm 2:15pm (45 mins)

Strategy and Business

Beyond IO: A future free from silos

  • Moderator Debi Amanti Belanger - Principal, ClearView Healthcare Partners
  • Panelist Philip Gotwals - Head, Search and Evaluation Strategic Alliances, Novartis Institutes for BioMedical Research, Inc.
  • Panelist Patrick Tricoli - CEO, Nanobiotix USA

2:30pm 3:15pm (45 mins)

Strategy and Business

What's the next big thing on pharma's wish list?

  • Moderator Ed Silverman - Senior Writer and Pharmalot Columnist, STAT News
  • Panelist Lizabeth Leveille - Associate VP and Head, Boston Innovation Hub, BD&L, Merck
  • Panelist Chandra Ramanathan - Head, East Coast Innovation Center, Bayer
  • Panelist Aaron Schwartz - Director, R&D Innovation Sourcing, Novo Nordisk Inc.

3:30pm 4:15pm (45 mins)

Strategy and Business

Cell and Gene Therapies: From discovery to commercialization

  • Panelist Michael Cooke - CSO, Magenta Therapeutics
  • Panelist Peter G. Nell - VP, Head Strategy and Business Development, Casebia Therapeutics

4:30pm 5:30pm (60 mins)

Strategy and Business

Closing Session

5:00pm 6:00pm (60 mins)

Networking

Closing reception